PAA, a novel metal chelator and metalloproteinase inhibitor significantly reduced amyloid plaque burden in an APP/tau mouse model of Alzheimer’s disease (AD)

Larry Schmued, Calvert Schmued, Bryan Maloney, Debomoy K Lahiri · 2025

Read PAA, a novel metal chelator and metalloproteinase inhibitor significantly reduced amyloid plaque burden in an APP/tau mouse model of Alzheimer’s disease (AD) by Larry Schmued, Calvert Schmued, Bryan Maloney, Debomoy K Lahiri (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713569.txt.

Description

Larry Schmued and co-authors test a metal-binding drug against Alzheimer's plaque buildup in mice, in this 2025 study. Metals help drive the clumping of amyloid, one of the proteins that pile up in the disease. Their compound, called PAA, both binds metals and blocks a protein-cutting enzyme class.

Mice bred to carry human Alzheimer's genes got the drug in their drinking water from four months of age. After nine months of dosing, treated mice showed no weight, behavior, or tissue problems. Their brains carried about two thirds of the plaque load seen in untreated mice. Two separate plaque stains agreed on the result. The authors present PAA as a candidate worth further study.

Catalog record

CREATORLarry Schmued, Calvert Schmued, Bryan Maloney, Debomoy K Lahiri
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11713569

Browse the full library · About the Tower of Babel